Media
News
Company announcements, financial statements, scientific results and regulatory milestones.
Investors
2025 ERC Financial Statements
Investors
2024 ERC Financial Statements
Investors
2023 ERC Financial Statements
Investors
CEO Statement 2023/2024
Investors
ERC Belgium balance sheet for the financial year ending 31 Dec 2022
Investors
CEO statement 2022/2023
Regulatory
ERC Granted FDA Fast Track Designation for Sitoiganap in Patients with Recurrent Glioblastoma
Science
ERC Announces Publication of Positive Efficacy Data with Sitoiganap in Patients with Recurrent Glioblastoma
Investors
ERC Belgium balance sheet for the financial year ending 31 Dec 2021
Investors
CEO statement 2021/2022
Regulatory
ERC-USA Announces FDA Recommendation for Early Termination of Phase 2 Clinical Trial of ERC1671/SITOIGANAP (Gliovac or Sitoiganap) and Application for Registration Trial for Treatment of Glioblastoma
Regulatory
ERC receives a positive Opinion to commence a paediatric investigation plan(clinical trial) from the European Medicines Agency.
Science
12 Month Progress Report 30/04/2019-30/04/2020
Investors
Latest situation – CEO statement
Science
In Q2 2020 after enrolling about 40 patients in the Phase II clinical trial, ERC will submit its request for commercialization in the USA
Company
Abigail-Alliance Humanitarian of the year award 2019
Regulatory
Decision of National organisation of Medicines of Greece
Science
12 month progress report 31/08/2017-31/09/2018
Company
New production site in the Netherlands
Regulatory
Approval for open phase II study
Company